Sermorelin
Also known as: GRF 1-29, GHRH 1-29, Geref
Overview
Sermorelin is a synthetic 29-amino acid peptide that represents the shortest fully functional fragment of endogenous growth hormone-releasing hormone (GHRH). It was FDA-approved as a diagnostic agent and later as a therapeutic for GH deficiency in children. Sermorelin's mechanism closely mimics the natural pulsatile GHRH release cycle, preserving the physiological negative feedback loop and making it a preferred choice in anti-aging and hormone optimization protocols.
Mechanism of Action
Sermorelin binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and secretion in a pattern that mirrors endogenous GHRH pulses. This pulsatile release maintains receptor sensitivity and avoids the desensitization associated with exogenous GH administration. Studies show it can double GH levels for up to 12 hours after injection, with peak levels around 2 hours. Half-life is approximately 11-12 minutes, resulting in a sharp physiological pulse.
Potential Benefits
- Preserves physiological pulsatile GH release pattern
- Supports natural negative feedback loop, reducing risk of pituitary suppression
- Improved body composition, lean mass, and fat reduction
- Enhanced sleep quality, particularly deep sleep stages
- Improved energy levels and recovery
- Anti-aging effects via GH/IGF-1 axis
- FDA historical approval provides established safety data
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 200-500 mcg/day |
| Beginner | 200-250 mcg at bedtime |
| Intermediate | 500 mcg at bedtime |
| Advanced | 500 mcg twice daily (bedtime + AM fasted) |
| Cycle Duration | 3-6 months continuous |
| Cycle Off | 1-2 months; may rotate with CJC-1295 |
Best dosed at bedtime on an empty stomach to amplify the physiological nocturnal GH pulse. Short half-life (~11 min) preserves natural pulsatility. Often prescribed in physician-supervised anti-aging protocols.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — systemic distribution
Most common administration route for research peptides. Inject into abdominal fat, thigh, or upper arm. Rotate sites. standard research dose.
Intramuscular Injection High — with slightly faster onset than SC
Alternative route when deeper delivery or faster absorption is desired. Less commonly used than SC for most research peptides.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Sermorelin:
Longevity Stack
Sermorelin combined with telomere-supporting Epithalon and NAD+ precursors for broad longevity protocol. Cycled over 10-20 day blocks.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 3mg, 6mg, 9mg |
|---|---|
| BAC Water | 1ml per 3mg vial (yields 3000 mcg/ml) |
| Storage | Refrigerate at 2-8°C after reconstitution; discard unused portion after 30 days |
| Shelf Life | 30 days refrigerated; lyophilized stable at -20°C for 24+ months |
Need exact syringe measurements?
Amino Acid Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Side Effects & Safety
- Mild headache
- Flushing
- Injection site reactions
- Possible water retention at high doses
- Nausea (uncommon)
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Active Malignancy
Uncontrolled Diabetes Mellitus
Severe Cardiac Disease
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Insulin / Oral Hypoglycemics:
Pharmacokinetics
| Half-Life | ~11-12 minutes |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Sermorelin for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.